Pediatric Noninvasive Ventilation and Sleep Unit, AP-HP, Hôpital Necker-Enfants Malades, Paris, France
Pediatric Pulmonology, Hopital Armand-Trousseau, Paris, Île-de-France, France.
Arch Dis Child. 2024 Oct 18;109(11):918-923. doi: 10.1136/archdischild-2023-326782.
Dyspnoea and sleep-disordered breathing (SDB) are common in children with life-limiting conditions but studies on treatment with non-invasive ventilation (NIV) or continuous positive airway pressure (CPAP) are scarce. The aim of the study was to describe children treated with long-term NIV/CPAP within a paediatric palliative care programme in France.
Cross-sectional survey on children and young adults with complex medical conditions treated within the French paediatric NIV network with long-term NIV/CPAP. Characteristics of the patients were analysed and patient-related outcome measures of NIV/CPAP benefit were reported.
The data of 50 patients (68% boys), median age 12 (0.4-21) years were analysed. Twenty-three (46%) patients had a disorder of the central nervous system and 5 (10%) a chromosomal anomaly. Thirty-two (64%) patients were treated with NIV and 18 (36%) with CPAP. NIV/CPAP was initiated on an abnormal Apnoea-Hypopnoea Index in 18 (36%) of the patients, an abnormal nocturnal gas exchange alone in 28 (56%), and after an acute respiratory failure in 11 (22%) of the patients. Mean objective NIV/CPAP adherence was 9.3±3.7 hours/night. NIV/CPAP was associated with a decrease in dyspnoea in 60% of patients, an increase in sleep duration in 60% and in sleep quality in 74%, and an improvement in parents' sleep in 40%.
In children with life-limiting conditions, long-term NIV/CPAP may be associated with relief of dyspnoea, an improvement of SDB and an improvement in parents' sleep.
呼吸困难和睡眠呼吸障碍(SDB)在患有生命终末期疾病的儿童中很常见,但关于使用无创通气(NIV)或持续气道正压通气(CPAP)治疗的研究却很少。本研究的目的是描述在法国儿科姑息治疗计划中接受长期 NIV/CPAP 治疗的儿童。
对法国儿科 NIV 网络中接受长期 NIV/CPAP 治疗的患有复杂医疗条件的儿童和青少年进行横断面调查。分析了患者的特征,并报告了 NIV/CPAP 获益的患者相关结局指标。
共分析了 50 名患者(68%为男性)的数据,中位年龄为 12 岁(0.4-21 岁)。23 名(46%)患者存在中枢神经系统疾病,5 名(10%)患者存在染色体异常。32 名(64%)患者接受 NIV 治疗,18 名(36%)患者接受 CPAP 治疗。18 名(36%)患者因异常呼吸暂停低通气指数、28 名(56%)患者因异常夜间气体交换、11 名(22%)患者因急性呼吸衰竭而开始使用 NIV/CPAP。平均客观 NIV/CPAP 依从性为 9.3±3.7 小时/夜。NIV/CPAP 可使 60%的患者呼吸困难减轻,60%的患者睡眠时间延长,74%的患者睡眠质量改善,40%的患者父母睡眠改善。
在患有生命终末期疾病的儿童中,长期 NIV/CPAP 可能与缓解呼吸困难、改善 SDB 和改善父母睡眠有关。